Close Menu

Danaher

The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.

Cambridge, UK-based PredictImmune announced the entry of its first product, PredictSure IBD, into the National Institute for Health and Care Excellence (NICE) Diagnostic Assessment Programme (DAP), an initiative that evaluates new diagnostic technologies and guides people working in the UK's National Health Service in making decisions about adopting them.

A brief recap of Diagnostics news the week of Mar 8, 2019: Danaher, Labcorp, Quest, and More

Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.

Danaher has commenced its concurrent offerings of $1.35 billion of shares of its common stock and $1.35 billion of shares of its mandatory convertible preferred stock.

Danaher is financing the deal with $3 billion from an equity offering, cash on hand, and proceeds from an issuance of debt and/or new credit facilities.

The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.

Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time. 

A brief recap of the news for Jan 11, 2019: Danaher, Natera, Chembio, and More

A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.

Pages